Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Equity Ratio (2016 - 2025)

Coherus Oncology's Equity Ratio history spans 13 years, with the latest figure at 0.24 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 180.26% year-over-year to 0.24; the TTM value through Dec 2025 reached 0.24, up 180.26%, while the annual FY2025 figure was 0.24, 180.26% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.24 at Coherus Oncology, up from 0.17 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.27 in Q2 2025 and bottomed at 0.49 in Q1 2025.
  • The 5-year median for Equity Ratio is 0.12 (2024), against an average of 0.08.
  • The largest annual shift saw Equity Ratio tumbled 2406.41% in 2023 before it surged 318.78% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.14 in 2021, then plummeted by 298.66% to 0.29 in 2022, then decreased by 7.5% to 0.31 in 2023, then grew by 4.21% to 0.29 in 2024, then skyrocketed by 180.26% to 0.24 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Equity Ratio are 0.24 (Q4 2025), 0.17 (Q3 2025), and 0.27 (Q2 2025).